CD274 and esophageal adenocarcinoma: For example, in CheckMate 649, patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma were enrolled without restrictions on their cancer PD-L1 expression level, and were treated with nivolumab plus chemotherapy (CAPOX or FOLFOX), nivolumab plus ipilimumab, or chemotherapy alone [10, 17, 18].